Meeting Summary

Alabama Medicaid Agency
Pharmacy and Therapeutics (P&T) Committee

February 3, 2021

**Members Present:** Dr. Lee Carter, Dr. Kimberly Graham, Dr. Albert Holloway, Dr. Frances Heinze, Dr. Peter Hughes, Dr. Charles Nevels, Dr. Kelli Littlejohn Newman, and Dr. Melinda Rowe

**Members Absent:** None

**Presenters:** Dr. Rachel Bacon

Chairperson Carter called the Pharmacy and Therapeutics (P&T) Committee Meeting to order at 1:01 p.m. The minutes from the November 4, 2020 P&T Committee Meeting were approved with no objections. There was no old business.

**Pharmacy Program Update:**
Dr. Newman welcomed everyone to the third virtual P&T meeting and appreciates everyone’s attendance and flexibility. Today is the beginning of the legislative session. The public can view sessions on the ALISON website. Medicaid is continuing with quarterly P&T updates as well as virtual P&T and DUR board meetings. Virtual meetings will continue as long as permitted by the governor’s office. Each state is being allocated COVID-19 vaccinations. Medicaid does reimburse for administration of the vaccine. More information is available on the Medicaid website, and there is a specific ALERT pertaining to this topic. The Agency has extended the public health emergency through February 28, and decisions for extensions are currently made on a month-by-month basis.

**Pharmacotherapy Class Re-reviews (Please refer to the website for full text reviews.)**
University of Massachusetts Medical School Clinical Pharmacy Services presented 15 drug class re-reviews. The Skin and Mucous Membrane Antibacterials, Skin and Mucous Membrane Antivirals, Skin and Mucous Membrane Antifungals, Skin and Mucous Membrane Scabicides and Pediculicides, Skin and Mucous Membrane Miscellaneous Local Anti-infectives, Skin and Mucous Membrane Corticosteroids, Skin and Mucous Membrane Nonsteroidal Anti-inflammatory Agents, Skin and Mucous Membrane Miscellaneous Anti-inflammatory Agents, Skin and Mucous Membrane Antipruritics and Local Anesthetics, Skin and Mucous Membrane Astringents, Skin and Mucous Membrane Keratolytic Agents, Skin and Mucous Membrane Keratoplastic Agents, Skin and Mucous Membrane Miscellaneous Agents, and Skin and Mucous Membrane Cell Stimulants and Proliferants were last reviewed in November 2018. The Disease-Modifying Antirheumatic Drugs (DMARDs) were last reviewed in November 2020.